Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Feb 15, 2021; 13(2): 119-130
Published online Feb 15, 2021. doi: 10.4251/wjgo.v13.i2.119
Published online Feb 15, 2021. doi: 10.4251/wjgo.v13.i2.119
Table 4 Acute toxicity in all periods in both treatment groups
| Toxicity | Standard therapy, n (%) | TNT, n (%) | P value |
| During systemic ChT | 0.0371 | ||
| Without | 12 (24) | 16 (18) | |
| Grade 1-2 | 31 (62) | 70 (79) | |
| Grade 3 | 7 (14) | 3 (3) | |
| During CRT | 0.5531 | ||
| Without | 13 (18) | 21 (24) | |
| Grade 1-2 | 57 (79) | 64 (72) | |
| Grade 3-4 | 2 (3) | 4 (4) | |
| Postoperative complications | 0.140 | ||
| Without | 43 (61) | 62 (76) | |
| Grade 1-2 | 18 (26) | 15 (18) | |
| Grade 3-5 | 9 (13) | 5 (6) | |
- Citation: Tuta M, Boc N, Brecelj E, Peternel M, Velenik V. Total neoadjuvant therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure. World J Gastrointest Oncol 2021; 13(2): 119-130
- URL: https://www.wjgnet.com/1948-5204/full/v13/i2/119.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i2.119